This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Victor S. Fang, PhD
Departments of Medicine and Psychiatry

Barbara Warenica, MD
Department of Medicine

Herbert Y. Meltzer, MD
Department of Psychiatry Pritzker School of Medicine University of Chicago 950 E 59th St Chicago, IL 60637

Arch Gen Psychiatry. 1982;39(10):1217.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The dexamethasone suppression test (DST) is of great current interest in psychiatry because of the large body of evidence that some depressed patients fail to suppress cortisol levels to 5 µg/dL or less after an oral dose of 1.0 mg of dexamethasone.¹ Many psychiatrists have adopted this procedure as the first laboratory test of significance for clinical practice. Carroll et al pointed out a number of pitfalls in applying this test.¹ We wish to call attention to the need to assess rigorously the method of cortisol determination used by the clinical laboratories that carry out the test. Routine application of the 5-µg/dL cutoff could lead to a number of false-positive results, based on the results to be described.

Research laboratories, eg, those of Carroll, Sachar, and ourselves, use the competitive protein-binding assay (CPBA) method to measure plasma cortisol levels, whereas most clinical laboratories use commercial radioimmunoassay (RIA)kits. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?